Please login to the form below

Not currently logged in
Email:
Password:

Synairgen

This page shows the latest Synairgen news and features for those working in and with pharma, biotech and healthcare.

AZ severe asthma drug benralizumab backed by CHMP

AZ severe asthma drug benralizumab backed by CHMP

Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

Latest news

  • Setback for AZ as tralokinumab flunks asthma trial Setback for AZ as tralokinumab flunks asthma trial

    Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

  • AZ trial adds to pessimism about anti-IL-13 asthma drugs AZ trial adds to pessimism about anti-IL-13 asthma drugs

    Last year AZ's respiratory pipeline took a further knock when it halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma after deciding it

  • Synairgen sinks as AZ halts trial of asthma drug Synairgen sinks as AZ halts trial of asthma drug

    AZD9412 is an inhaled form of interferon beta partnered with UK company Synairgen, which saw its London Stock Exchange-listed shares lose more than a third of their value yesterday when ... For Synairgen, the setback lends greater importance to its

  • AZ licenses asthma infection drug from Synairgen AZ licenses asthma infection drug from Synairgen

    Boosts respiratory portfolio with $232m deal. AstraZeneca (AZ) has added to its portfolio of respiratory drug candidates after licensing an inhaled interferon beta therapy from Synairgen which is in trials to ... AZ is paying UK-based Synairgen $7.25m

  • Pharma continues to attract investors

    Synairgen raises fresh cash for asthma and pulmonary disease research. Synairgen, the drug research company, rose just over 1p to 19p following a share placing at 17p to raise £6.35m – ... The cash produced by the discounted placing is to go towards

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics